Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04757610 · ClinicalTrials.gov registry record · Phase 3
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
A Phase 3 study, sponsored by Opthea Limited.
- Terminated
- Registry status
- Phase 3
- Development phase
- 986
- Enrollment target
NCT04757610 is a Phase 3 study that was terminated before completion, run by Opthea Limited. The registered enrollment target is 986 participants.
The verdict
NCT04757610, a Phase 3 study, was terminated before completion, sponsored by Opthea Limited.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 986 participants
- Enrollment target
Study Summary
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Interventions
- PROCEDURE Sham
- BIOLOGICAL 2.0 mg OPT-302
- BIOLOGICAL 0.5 mg ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 986 participants |
| Start Date | 2021-03-12 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04757610
The ClinicalTrials.gov registry entry for NCT04757610 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 986 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Opthea Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham is the first listed.
NCT04757610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04757610 about?
NCT04757610 is a clinical study titled "OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)". A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
What is the current status of trial NCT04757610?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 986 participants. The study started on 2021-03-12. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT04757610?
The interventions under investigation include: Sham (PROCEDURE), 2.0 mg OPT-302 (BIOLOGICAL), 0.5 mg ranibizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04757610?
This trial is sponsored by Opthea Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.